

Effects Of Hesperidin and Nepitrin (*Salvia rosmarinus*) On the Response of GABA_A Receptors Expressed In *Xenopus* Oocytes and their Neuropharmacological Activities

ABSTRACT

Salvia rosmarinus, previously known as *Rosmarinus officinalis*, has intense pleasant smell reminiscent of pine wood[A]. *S. rosmarinus* has been widely used in traditional medicines and has long been known as the herb of remembrance. However, few studies have investigated the effects of non-volatile components of rosemary on central nervous system function. In this study, Bio-assay guided fractionation of the butanolic extract of *S. Rosmarinus* led to the isolation of two compounds hesperidin and nepitrin. Hesperidin and nepitrin were evaluated on recombinant $\alpha_1\beta_2\gamma_{2L}$ GABA_A receptors expressed in *Xenopus laevis* oocytes. Hesperidin and nepitrin were found to be flumazenil insensitive negative allosteric modulators of high concentrations of GABA at $\alpha_1\beta_2\gamma_{2L}$ GABA_A receptors. Hesperidin and nepitrin allosterically inhibit the response of GABA at $\alpha_1\beta_2\gamma_{2L}$ GABA receptors via a site other than the high-affinity benzodiazepine binding site.

INTRODUCTION

γ -Aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the mammalian central nervous system (CNS) activating neurons through several pharmacologically and structurally different receptor subtypes. GABA plays a crucial role in the excitatory: inhibitory balance in neuronal networks by inhibiting glutamatergic pyramidal neurons [1, 2]. GABA_A receptors are chloride channels that can be activated by GABA and modulated by other several drugs, [3] which are composed of pentameric channels formed by the combination of three distinct subunits, according to the following stoichiometry: $2\alpha:2\beta:1\gamma$. The GABA_A receptor is

possibly the most complex member of the nicotinoid superfamily containing five major ligand binding sites for GABA, benzodiazepines, barbiturates, picrotoxin, and neurosteroids [4, 5]. The additional binding sites serve to allosterically modulate the response of the receptor to GABA. Allosteric modulators have no direct action on the GABA_A receptor. GABA also activates GABA_B receptors, which are widely distributed throughout the mammalian brain and spinal cord [6]. GABA_B receptors are G-protein-coupled receptors (GPCRs) that function as heterodimers of GABA_{B1} and GABA_{B2} subunits [7, 8].

Salvia Rosmarinus, (previously known as *Rosmarinus officinalis*), belongs to Lamiaceae family. Lot of studies of different species of Lamiaceae family and their effects on memory, anxiety, depression, and sleep disorders [9]. *S. rosmarinus* intense pleasant smell reminiscent of pine wood. *S. Rosmarinus*, traditionally known as rosemary, it is important medicinal plant which grows all over the world specially in most Mediterranean countries [10, 11]. It is often cultivated for its aromatic oil. *S. Rosmarinus* has a long history of being used in traditional medicine and its antioxidant properties are well known [12, 13]. *S. Rosmarinus* has the capability to release the symptoms caused by respirational disorders, to stimulate hair growth, to reduce stress and mental alertness, and to treat Rheumatoid disease. Moreover it has a long history of being a herb of remembrance [14] and it is believed that memory is enhanced by the use of this plant [15, 16]. An extract of *S. Rosmarinus* was found to enhance the production of the nerve growth factor (NGF), a protein vital for the growth and functional maintenance of nerve tissue [17]. Carnosol, a major constituent of *S. Rosmarinus*, significantly increased the amount of tyrosine hydroxylase indicating that it may be effective for the treatment for Parkinson's disease (PD) [18]. The aerial parts of *S. Rosmarinus* have been shown to possess antinociceptive activity [19]. Thujone, constituent of the essential oil of *S. Rosmarinus*, was found to modulate GABA_A receptor.[20] Rosmarinic acid proved to have antidepressive activity and significantly reduces the duration of response in the forced

swimming test and decreases the defensive freezing behaviour of mice exposed to conditioned fear stress [21, 22], and increased the number of entries in the open arms during plus-maze task, suggesting an anxiolytic-like activity in rat [23]. Isolated compounds from *S. Rosmarinus* have shown to exert biphasic modulation of GABA_A receptors, demonstrated CNS activity in mouse models of antinociception, antidepressant and anxiolysis [24]. The action of salvigenin, rosmanol, and hispidulin acted as positive modulators when applied in the presence of low concentrations of GABA but in the presence of high concentrations of GABA acted as negative modulators, demonstrating a biphasic action [25]. Nepitrin, isolated from *S. Rosmarinus*, was evaluated for its memory enhancing effects. Nepitrin was found to dose-dependently inhibit AChE and BuChE enzymes. The observed effect was comparable to donepezil (AChE inhibitor) suggesting that nepitrin may have a mechanism of action similar to that of donepezil, which was supported by molecular docking studies. *In vivo* studies for the memory enhancing effect of nepitrin was also demonstrated. In the Y-maze task nepitrin was found to reverse scopolamine induced amnesia and increase the discrimination index in the novel object recognition test NORT [26]. The antinociceptive activity of hesperidin was assessed using the pain induced functional impairment (PIFIR) model in rats and capsaicin-induced nociception in mice. Hesperidin was found to exhibit a dose dependent antinociceptive activity. The antinociceptive effect produced by hesperidin in the PIFIR model was reduced by 36% with capsazepine pretreatment (TRPV1 selective antagonist) suggesting the involvement of the vanilloid (TRPV1) receptors [27]. The current study reports the effects of the non-volatile constituents' hesperidin and nepitrin (Figure 1) on recombinant $\alpha_1\beta_2\gamma_{2L}$ GABA_A receptors expressed in *Xenopus laevis* oocytes.




Figure 1: Chemical structures of hesperidin and neperin

MATERIAL AND METHODS

Plant Materials

The dried *S. Rosmarinus* plants were purchased from herbal markets located in Amman. The plants were identified by Prof. Dawud AL-Eisawi (Department of Biological Sciences, Faculty of Science, University of Jordan). Voucher specimens were deposited at the herbarium of the University of Jordan.

Chemicals, Materials, Instrumentation and Drugs

All chemicals used were purchased from Aldrich Chemical Co. Ltd (St Louis, MO, USA) and were of highest commercially available purity. Silica gel for column chromatography (CC) was performed on silica gel (Merck silica gel 60H, particle size 5 - 40 μm) and Sephadex LH-20 gel. Thin layer chromatography (TLC) was performed on Merck aluminium backed plates, pre-coated with silica (0.2 mm, 60F254). UV-Spectra were recorded on Hitachi U-2000 double beam UV/Vis Spectrophotometer. Mass spectra were carried out on a Thermo Finnigan (Waltham, MA, USA) PolarisQ Ion Trap system using a direct exposure probe. Nuclear magnetic resonance ^1H NMR and ^{13}C NMR spectra were recorded at 400 and 100 MHz,

respectively on a Varian Gemini spectrometer (Palo Alto CA, USA). Melting points were determined using a Stuart (Stone, Staffordshire, UK) SMP10 melting point apparatus.

Preparation of the Extracts and Solvent Fractionation

The plant was dried and ground into fine powder (5 Kg). Defatting was done by extraction with petroleum ether (40 L) at room temperature for 7 days. The residual materials were then extracted by ethanol (3 times, 10 days each, 50 L) at room temperature to isolate the secondary metabolites. The combined crude ethanolic extracts were evaporated under vacuum. The resulting crude extract was partitioned between chloroform and water (1:1 v/v). The less polar organic compounds were extracted from water by *n*-butanol to give the butanol extract.

Isolation of Constituents

The butanol extract of *S. Rosmarinus* (10 g) was adsorbed on 20 g silica gel and subjected to column chromatography ($\Phi 28 \times 4.5$ cm). The columns were packed in chloroform and the polarity increased gradually by using methanol, until pure methanol was added resulting in four fractions (RVI-IX) according to their TLC fingerprint. Each fraction was further purified by a combination of column chromatography and preparative thin layer chromatography using suitable solvent systems.

Yellow powder precipitated during treatment of fraction RVI with methanol. Then this powder was further washed with water to yield 60 mg of hesperidin (hesperetin-7-O-rutinoside(-Glc6-Rha)) as a pure yellow powder. Fraction RVII was washed with methanol to yield a yellow precipitate. Further washing of this solid with water afforded nepitrin (nepitrin-7-O-glucoside) which was soluble in the water layer.

Physical and spectroscopic data of the isolated compounds

Hesperidin: yellow powder; Melting point (m.p): 252-257 °C; UV λ_{\max} (MeOH) nm: 332

(Band I), 283 (Band II); +NaOMe, 367, (Band I), 285 (Band II); +AlCl₃, 353 (Band I), 285 (Band II); +HCl, 332 (Band I), 283 (Band II); ESMS m/z (%): 609 [M-H]⁻ (100), 301.0 [M-(Rha-Glc)+H]⁺ (14), 431.1 (7); ¹H-NMR (DMSO-*d*₆) δ ppm: 12.0 (1H, s, 5-OH), 6.92 (1H, d, *J*=4.4 Hz, H-5'), 6.90 (1H, dd, *J*=9.8, 2 Hz, H-6'), 6.87 (1H, d, *J*=2 Hz, H-2'), 6.12 (1H, d, *J*=2.4 Hz, H-8), 6.10 (1H, d, *J*=2.4 Hz, H-6), 5.48 (1H, dd, *J*=12.4, 3 Hz, H-2), 4.95 (1H, d, *J*=7.6 Hz, H-1''), 4.50 (1H, s, H-1'''), 3.76 (3H, s, 4'-OMe), 3.24 (1H, dd, *J*=13.2, 4 Hz, H-3β), 2.75 (1H, dd, *J*=17.2, 3.2 Hz, H-3α), 1.06 (3H, d, *J*=6 Hz, H-6'''); ¹³C-NMR (DMSO-*d*₆) δ ppm: 197.5 (C-4), 165.6 (C-7), 163.5 (C-5), 162.9 (C-9), 148.4 (C-4'), 146.9 (C-3'), 131.3 (C-1'), 118.4 (C-6'), 114.6 (C-2'), 112.5 (C-5'), 103.7 (C-10), 101.0 (C-1'''), 99.9 (C-1''), 96.8 (C-6), 96.0 (C-8), 78.8 (C-2), 76.7 (C-5''), 76.0 (C-3''), 73.4 (C-4'''), 72.5 (C-2''), 71.1 (C-4''), 70.7 (C-3'''), 70.0 (C-2'''), 68.8 (C-5'''), 66.5 (C-6''), 56.1 (4'-OMe), 42.5 (C-3), 18.3 (C-6''').

Nepitrin: yellow powder; ESMS m/z (%): 476.8 [M-H]⁺ (100), 314.9 (7), 299.7 [M-(Glc)+H]⁺ (9); ¹H-NMR (DMSO-*d*₆) δ ppm: 8.02 (1H, d, *J*=8.8 Hz, H-5'), 7.51 (1H, d, *J*=2 Hz, H-2'), 7.48 (1H, dd, *J*=7, 1.8 Hz, H-6'), 7.08 (1H, s, H-3), 6.80 (1H, s, H-8), 4.95 (1H, d, *J*=7.6 Hz, H-1''), 3.83 (3H, s, 6-OMe); ¹³C-NMR (DMSO-*d*₆) δ ppm: 182.6 (C-4), 165.0 (C-2), 156.9 (C-9), 152.9 (C-7), 152.6 (C-5), 150.6 (C-4'), 146.3 (C-3'), 132.9 (C-6), 121.8 (C-1'), 119.6 (C-6'), 116.4 (C-5'), 113.9 (C-2'), 106.1 (C-10), 103.1 (C-3), 100.6 (C-1''), 94.7 (C-8), 77.7 (C-5''), 77.1 (C-4''), 73.6 (C-2''), 70.0 (C-3''), 61.1 (C-6''), 60.7 (6-OMe).

Pharmacological Analysis

Electrophysiological evaluation of the final extract and the isolated compounds from *S. Rosmarinus* was carried out on functional assays using two-electrode voltage clamp methods on recombinant GABA receptors expressed in *Xenopus laevis* oocytes using the methods described previously [28].

Drugs and Chemicals

Diazepam was kindly donated by the Department of Pharmacy, University of Peshawar. Imipramine, DMSO, Tween solution (TWEEN® 80, Sigma-Aldrich Co. LLC, USA), methanol (Merck, Germany) and tramadol hydrochloride and flumazenil (98%, Sigma-Aldrich, USA) and pentylenetetrazol (Tokyo chemical industries Co Ltd) were purchased for the study. All chemicals and solvents used in this research were of analytical grade.

RESULTS

Electrophysiology

Hesperidin produced no effect on sham-injected oocytes or at $\alpha_1\beta_2\gamma_{2L}$ GABAA receptors when administered alone. Hesperidin inhibited currents due to 100 μ M GABA with an IC_{50} of 42.95 μ M (95% CI: 19.62 to 93.98) and a Hill coefficient of 1.08 ± 0.95 (figure 2). Hesperidin was not affected by the addition of 10 μ M flumazenil neither at high nor at low concentrations of GABA. The maximum concentration of hesperidin applied was 100 μ M due to its solubility.




Figure 2. Effect of hesperidin in the presence of GABA (100 μ M) at $\alpha_1\beta_2\gamma_{2L}$ GABA_A receptors expressed in *Xenopus* oocytes. Data are the mean \pm SEM (n=3–6 oocytes)

GABA dose response curves were carried out both without and with hesperidin (100 μM) at $\alpha_1\beta_2\gamma_2\text{L}$ GABA_A receptors (figure 3) with an EC₅₀ of 782 μM (95% CI: 29.37 to 20834) and a Hill coefficient of 2.89 ± 0.71 .




Figure 3. Dose response curves of GABA (●) and GABA in the presence of 100 μM (◇) hesperidin at human $\alpha_1\beta_2\gamma_2\text{L}$ GABA_A receptors expressed in *Xenopus* oocytes. Data are the mean \pm SEM (n=3–6 oocytes)

Nepitrin produced no effect on sham-injected oocytes or at $\alpha_1\beta_2\gamma_2\text{L}$ GABA_A receptors when administered alone but inhibited currents due to 100 μM GABA with an IC₅₀ of 98.7 μM (95% CI: 64.41 to 151.4) and a Hill coefficient of 2.12 ± 0.77 (figure 4) and shifted the GABA dose response curves at $\alpha_1\beta_2\gamma_2\text{L}$ GABA_A receptors to the right, increasing the mean GABA EC₅₀ from 123.3 to 193.6 μM (95% CI: 141.4 to 265.1), with a Hill slope of 1.05 ± 0.15 (compared to 0.73 ± 0.07 in the case of GABA alone) (figure 5). Nepitrin was not affected by the addition of 10 μM flumazenil neither at high nor at low concentrations of GABA.




Figure 4. Effect of nepitrin in the presence of GABA (100 μM) at $\alpha_1\beta_2\gamma_2\text{L}$ GABA_A receptors expressed in *Xenopus* oocytes. Data are the mean \pm SEM (n=3–6 oocytes)




Figure 5. Dose response curves of GABA (●) and GABA in the presence of 100 μM (◊) nepitrin at human $\alpha_1\beta_2\gamma_2\text{L}$ GABA_A receptors expressed in *Xenopus* oocytes. Data are the mean \pm SEM (n=3–6 oocytes)

EC₅₀ and IC₅₀ values were unable to be calculated for most of the compounds investigated due to solubility limits. However, for comparison Table 1 summarizes the effect of 100 μM of each compound on the maximal response and EC₅ GABA response.

Table 1 Percentage inhibition and enhancement values for the isolated compounds

| Compound | % Inhibition ^a | % Enhancement ^b |
|------------|---------------------------|----------------------------|
| Hesperidin | 52.6 | - |
| Nepitrin | 18.3 | - |

^a percentage inhibition of maximal GABA response by 100 μM compound

^b percentage enhancement of GABA EC₅ response by 100 μM compound

DISCUSSION

Hesperidin has previously been found to have sedative and sleep enhancing properties and when injected concurrently with diazepam the sedative effect is greatly increased [29-31]. However, hesperidin did not potentiate the response of $\alpha 1\beta 2\gamma 2$ GABA_A receptors to low doses of GABA, supporting the suggestion that the sedative effects of hesperidin are not mediated via GABA receptors [29]. Systemic administration of hesperidin produced a significant reduction in the phosphorylation state of extracellular signal-regulated kinases 1/2 (pERK 1/2) in the cerebral cortex, cerebellum and hippocampus. However, no effect on pERK 1/2 was found for neohesperidin which lacks sedative properties [32]. A study by Loscalzo *et al.* has also suggested the involvement of opioid receptors in the sedative and antinociceptive effects of hesperidin [33]. At high doses of GABA (100 μM) hesperidin inhibited the GABA response with an IC₅₀ of 42.95 μM. GABA dose response curves were carried out both without and with

hesperidin (100 μM), at $\alpha_1\beta_2\gamma_2\text{L GABA}_A$ receptors hesperidin shifted the GABA dose response curve to the right with an EC_{50} of 782 μM . The effect of hesperidin was not altered by the addition flumazenil either at high or low concentrations of GABA indicating that actions of hesperidin are not mediated via high-affinity benzodiazepine sites. This is consistent with the finding that hesperidin was unable to modify [3H]-flunitrazepam binding to rat cerebral cortex synaptosomal membranes [29].

Nepitrin has been reported to exert anti-pyretic and weak analgesic activity [34]. To date, no studies have investigated the action of nepitrin at GABA_A receptors. Nepitrin inhibited currents due to 100 μM GABA with an IC_{50} of 98.7 μM and shifted the GABA dose response curves at $\alpha_1\beta_2\gamma_2\text{L GABA}_A$ receptors to the right, with an EC_{50} of 193.6 μM , indicating that nepitrin acts as a negative modulator at this receptor, and is more potent than hesperidin. The action of nepitrin was not affected by the addition of flumazenil at either high or at low concentrations of GABA indicating that nepitrin does not act at the 'high-affinity' benzodiazepine binding site. Both hesperidin and nepitrin were found to be insensitive to flumazenil at both high and low concentrations of GABA.

References

1. Krnjevic, K. and S. Schwartz, *The action of gamma-aminobutyric acid on cortical neurones*. Exp Brain Res, 1967. **3**(4): p. 320-36.
2. Ticku, M.K., *Differences in gamma-aminobutyric acid receptor sensitivity in inbred strains of mice*. Journal of Neurochemistry, 1979. **33**(5): p. 1135-1138.
3. Stephenson, F.A., *The GABAA receptors*. Biochem J, 1995. **310** (Pt 1): p. 1-9.
4. DeLorey, T.M. and R.W. Olsen, *Gamma-aminobutyric acidA receptor structure and function*. J Biol Chem, 1992. **267**(24): p. 16747-50.
5. Macdonald, R.L. and R.W. Olsen, *GABAA receptor channels*. Annu Rev Neurosci, 1994. **17**: p. 569-602.
6. Bowery, N.G., et al., *Bicuculline-insensitive GABA receptors on peripheral autonomic nerve terminals*. Eur J Pharmacol, 1981. **71**(1): p. 53-70.
7. Calver, A.R., et al., *The C-terminal domains of the GABA(b) receptor subunits mediate intracellular trafficking but are not required for receptor signaling*. J Neurosci, 2001. **21**(4): p. 1203-10.
8. Martin, S.C., S.J. Russek, and D.H. Farb, *Human GABA(B)R genomic structure: evidence for splice variants in GABA(B)R1 but not GABA(B)R2*. Gene, 2001. **278**(1-2): p. 63-79.
9. Abdelhalim, A. and J.J.S.i.N.P.C. Hanrahan, *Biologically active compounds from Lamiaceae family: Central nervous system effects*. 2021. **68**: p. 255-315.
10. Stefanaki, A. and T. van Andel, *Mediterranean aromatic herbs and their culinary use*, in *Aromatic Herbs in Food*. 2021, Elsevier. p. 93-121.
11. Abdelhalim, A., et al., *Medicinal plants used by traditional healers in Jordan, the Tafila region*. 2017. **13**(Suppl 1): p. S95.
12. Rašković, A., et al., *Antioxidant activity of rosemary (Rosmarinus officinalis L.) essential oil and its hepatoprotective potential*. 2014. **14**(1): p. 1-9.
13. Klančnik, A., et al., *In vitro antimicrobial and antioxidant activity of commercial rosemary extract formulations*. 2009. **72**(8): p. 1744-1752.
14. Duke, J.A., *Alzheimeretto*. Journal of Medicinal Food, 1998. **1**(1): p. 53.
15. James Rouse, N.D., *Ginkgo biloba: Mind, Mood, and Memory*. JOURNAL OF APPLIED NUTRITIONAL SCIENCE, 1998. **6**(7): p. 1-2.
16. Perry, E.K., et al., *Medicinal Plants and Alzheimer's Disease: Integrating Ethnobotanical and Contemporary Scientific Evidence*. The Journal of Alternative and Complementary Medicine, 1998. **4**(4): p. 419.
17. Kosaka, K. and T. Yokoi, *Carnosic acid, a component of rosemary (Rosmarinus officinalis L.), promotes synthesis of nerve growth factor in T98G human glioblastoma cells*. Biol Pharm Bull, 2003. **26**(11): p. 1620-2.
18. Kim, S.J., et al., *Carnosol, a component of rosemary (Rosmarinus officinalis L.) protects nigral dopaminergic neuronal cells*. Neuroreport, 2006. **17**(16): p. 1729-33.
19. Gonzalez-Trujano, M.E., et al., *Evaluation of the antinociceptive effect of Rosmarinus officinalis L. using three different experimental models in rodents*. J Ethnopharmacol, 2007. **111**(3): p. 476-82.
20. **Hold**, K.M., et al., *±-Thujone (the active component of absinthe): \hat{I}^3 -Aminobutyric acid type A receptor modulation and metabolic detoxification*. Proceedings of the National Academy of Sciences of the United States of America, 2000. **97**(8): p. 3826-3831.

21. Takeda, H., et al., *Rosmarinic acid and caffeic acid reduce the defensive freezing behavior of mice exposed to conditioned fear stress*. *Psychopharmacology (Berl)*, 2002. **164**(2): p. 233-5.
22. Takeda, H., et al., *Rosmarinic acid and caffeic acid produce antidepressive-like effect in the forced swimming test in mice*. *Eur J Pharmacol*, 2002. **449**(3): p. 261-7.
23. Pereira, P., et al., *Neurobehavioral and genotoxic aspects of rosmarinic acid*. *Pharmacol Res*, 2005. **52**(3): p. 199-203.
24. Abdelhalim, A., et al., *Antidepressant, anxiolytic and antinociceptive activities of constituents from Rosmarinus officinalis*. 2015. **18**(4): p. 448-459.
25. Abdelhalim, A., et al., *GABAA Receptor Modulation by Compounds Isolated from Salvia triloba L*. 2014. **4**(02): p. 148.
26. Karim, N., et al., *Molecular docking and anti-amnesic effects of nepitrin isolated from Rosmarinus officinalis on scopolamine-induced memory impairment in mice*. 2017. **96**: p. 700-709.
27. Martínez, A.L., et al., *Hesperidin produces antinociceptive response and synergistic interaction with ketorolac in an arthritic gout-type pain in rats*. *Pharmacol. Biochem. Behav.*, 2011. **97**(4): p. 683-689.
28. Karim, N., et al., *Potency of GABA at human recombinant GABA A receptors expressed in Xenopus oocytes: a mini review*. 2013. **44**: p. 1139-1149.
29. Fernández, S.P., et al., *Central nervous system depressant action of flavonoid glycosides*. 2006. **539**(3): p. 168-176.
30. Fernández, S.P., et al., *Synergistic interaction between hesperidin, a natural flavonoid, and diazepam*. 2005. **512**(2-3): p. 189-198.
31. Marder, M., et al., *6-Methylapigenin and hesperidin: new valeriana flavonoids with activity on the CNS*. 2003. **75**(3): p. 537-545.
32. Martínez, M.C., et al., *Hesperidin, a flavonoid glycoside with sedative effect, decreases brain pERK1/2 levels in mice*. 2009. **92**(2): p. 291-296.
33. Loscalzo, L.M., et al., *Opioid receptors are involved in the sedative and antinociceptive effects of hesperidin as well as in its potentiation with benzodiazepines*. 2008. **580**(3): p. 306-313.
34. Agarwal, O.J.A. and actions, *The anti-inflammatory action of nepitrin, a flavonoid*. 1982. **12**: p. 298-302.